Fundraising FoxLunac Therapeutics
Leeds, GB · 1 known investors
Find your way into Lunac Therapeutics
Sign up to see every warm intro you have to Lunac Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lunac Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
LUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk. The company focuses on cardiovascular and blood coagulation therapies for patients requiring anticoagulation.
Founders & leadership
Investors · 1
How we know: Epidarex Capital's portfolio page · the Companies House PSC register · open dataset · 5k.vc investor directory · Not right? Tell us
Companies House · registry record
View on Companies House ↗- Registered name
- LUNAC THERAPEUTICS LIMITED
- Company number
- 11317849
- Status
- Liquidation
- Company type
- Private limited company
- Incorporated
- 18 Apr 2018
- Registered office
- 29 Craven Street, London, WC2N 5NT
- Nature of business (SIC)
- 72190 — Other research and experimental development on natural sciences and engineering
- Accounts
- last made up to 31 May 2024 · next due 28 Feb 2026
- Confirmation statement
- last made up to 17 Apr 2025 · next due 1 May 2026
Current officers · 4
- Mary Eugenie Canning — director, appointed 20 Sept 2019
- Peter Michael Finan — director, appointed 20 Sept 2019
- Helen Philippou — director, appointed 18 Apr 2018
- Mervyn Turner — director, appointed 4 Oct 2019
Source: Companies House public register · retrieved 3 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Lunac Therapeutics do?
- LUNAC Therapeutics develops first-in-class oral and intravenous anticoagulants targeting activated Factor XII to treat and prevent thrombotic events with reduced bleeding risk. The company focuses on cardiovascular and blood coagulation therapies for patients requiring anticoagulation.
- Who founded Lunac Therapeutics?
- Lunac Therapeutics was founded by Professor Helen Philippou, Dr. Richard Foster.
- Who are Lunac Therapeutics's investors?
- Lunac Therapeutics's investors include Epidarex Capital.
- Where is Lunac Therapeutics headquartered?
- Lunac Therapeutics is headquartered in Leeds, GB.